Histone deacetylase inhibitors exert anti-tumor effects on human adherent and stem-like glioma cells
Open accessAbstract
BACKGROUND: The diagnosis of glioblastoma (GBM), a most aggressive primary brain tumor with a median survival of 14.6 months, carries a dismal prognosis. GBMs are characterized by numerous genetic and epigenetic alterations, affecting patient survival and treatment response. Epigenetic mechanisms are deregulated in GBM as a result of aberrant expression/activity of epigenetic enzymes, including histone deacetylases (HDAC) which remove acetyl groups from histones regulating chromatin accessibility. Nevertheless, the impact of class/isoform-selective HDAC inhibitors (HDACi) on glioma cells, including glioma stem cells, had not been systematically determined. RESULTS: Comprehensive analysis of the public TCGA dataset revealed the increased expression of HDAC 1, 2, 3, and 7 in malignant gliomas. Knockdown of HDAC 1 and 2 in human GBM cells significantly decreased cell proliferation. We tested the activity of 2 new and 3 previously described HDACi with different class/isoform selectivity on human GBM cells. All tested compounds exerted antiproliferative properties on glioma cells. However, the HDACi 1 and 4 blocked proliferation of glioblastoma cells leading to G2/M growth arrest without affecting astrocyte survival. Moreover, 1 and 4 at low micromolar concentrations displayed cytotoxic and antiproliferative effects on sphere cultures enriched in glioma stem cells. CONCLUSIONS: We identified two selective HDAC inhibitors that blocked proliferation of glioblastoma cells, but did not affect astrocyte survival. These new and highly effective inhibitors should be considered as promising candidates for further investigation in preclinical GBM models.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Impairment of HDAC1/2 activities both genetically and pharmacologically impairs cell proliferation and survival.
“Consequently, impairment of HDAC1/2 activities both genetically and pharmacologically impairs cell proliferation and survival (Was et al., 2019).”
From HDACs and the epigenetic plasticity of cancer cells: target the complexity (2022) · cites this paper as Was et al., 2019
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Ostrom, Q. T., Gittleman, H. R., Farah, P., Ondracek, A., Chen, Y., Wolinsky, Y., Stroup, N. E., Kruchko, C. A., & Barnholtz‐Sloan, J. S. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not151 · Cited by 12,049 · see citing works
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735 · see citing works
Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma
Patel, A. P., Tirosh, I., Trombetta, J. J., Shalek, A. K., Gillespie, S. M., Wakimoto, H., Cahill, D. P., Nahed, B. V., Curry, W. T., Martuza, R. L., et al. (2014) · Science · doi:10.1126/science.1254257 · Cited by 5,063 · see citing works
The Somatic Genomic Landscape of Glioblastoma
Brennan, C. W., Verhaak, R. G. W., McKenna, A., Campos, B., Noushmehr, H., Salama, S. R., Zheng, S., Chakravarty, D., Sanborn, J. Z., Berman, S. H., et al. (2013) · Cell · doi:10.1016/j.cell.2013.09.034 · Cited by 5,016 · see citing works
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas
The Cancer Genome Atlas Research Network (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1402121 · Cited by 3,148 · see citing works
Ostrom, Q. T., Gittleman, H. R., Liao, P., Vecchione-Koval, T., Wolinsky, Y., Kruchko, C., & Barnholtz‐Sloan, J. S. (2017) · Neuro-Oncology · doi:10.1093/neuonc/nox158 · Cited by 1,804 · see citing works
Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders
Falkenberg, K. J., & Johnstone, R. W. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4360 · Cited by 1,564 · see citing works
New and emerging HDAC inhibitors for cancer treatment
West, A. C., & Johnstone, R. W. (2014) · Journal of Clinical Investigation · doi:10.1172/jci69738 · Cited by 1,404 · see citing works
Cancer stem cells: current status and evolving complexities.
Visvader, J., & Lindeman, G. (2012) · Cell Stem Cell · doi:10.1016/j.stem.2012.05.007 · Cited by 1,299 · see citing works
The role of glioma stem cells in chemotherapy resistance and glioblastoma multiforme recurrence
Auffinger, B., Spencer, D. A., Pytel, P., Ahmed, A. U., & Lesniak, M. S. (2015) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2015.1051968 · Cited by 293 · see citing works
Pimelic Diphenylamide 106 Is a Slow, Tight-binding Inhibitor of Class I Histone Deacetylases
Chou, C. J., Herman, D., & Gottesfeld, J. M. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m807045200 · Cited by 223 · see citing works
The Evidence of Glioblastoma Heterogeneity
Soeda, A., Hara, A., Kunisada, T., Yoshimura, S., Iwama, T., & Park, D. M. (2015) · Scientific Reports · doi:10.1038/srep07979 · Cited by 202 · see citing works
Lee, J.-J., Kim, B. C., Park, M.-J., Lee, Y., Kim, Y.-N., Lee, B. L., & Js, L. (2010) · Cell Death and Differentiation · doi:10.1038/cdd.2010.139 · Cited by 175 · see citing works
Ellert‐Miklaszewska, A., Kamińska, B., & Konarska, L. (2004) · Cellular Signalling · doi:10.1016/j.cellsig.2004.05.011 · Cited by 167 · see citing works
Lucio-Eterovic, A. K., Cortez, M. A. A., Valera, E. T., Motta, F., Queiróz, R. G. D. P., Machado, H. R., Carlotti, C. G., Neder, L., Scrideli, C. A., & Tone, L. G. (2008) · BMC Cancer · doi:10.1186/1471-2407-8-243 · Cited by 156 · see citing works
Chiao, M., Cheng, W.-Y., Yang, Y., Shen, C., & Ko, J. (2013) · Autophagy · doi:10.4161/auto.25664 · Cited by 135 · see citing works
Zhang, L., Han, Y., Jiang, Q., Wang, C., Chen, X., Li, X., Xu, F., Jiang, Y., Wang, Q., & Xu, W. (2014) · Medicinal Research Reviews · doi:10.1002/med.21320 · Cited by 130 · see citing works
Carén, H., Stricker, S. H., Bulstrode, H. J. C. J., Gagrica, S., Johnstone, E. R., Bartlett, T. E., Feber, A., Wilson, G. A., Teschendorff, A. E., Bertone, P., et al. (2015) · Stem Cell Reports · doi:10.1016/j.stemcr.2015.09.014 · Cited by 120 · see citing works
Eyüpoglu, I. Y., Hahnen, E., Buslei, R., Siebzehnrübl, F. A., Savaskan, N. E., Lüders, M., Tränkle, C., Wick, W., Weller, M., Fahlbusch, R., et al. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03098.x · Cited by 115 · see citing works
Broadley, K. W. R., Hunn, M. K., Farrand, K. J., Price, K. M., Grasso, C., Miller, R. J., Hermans, I. F., & McConnell, M. J. (2010) · Stem Cells · doi:10.1002/stem.582 · Cited by 114 · see citing works
Zhou, N., Moradei, O. M., Raeppel, S. L., Leit, S. M., Fréchette, S., Gaudette, F., Paquin, I., Bernstein, N., Bouchain, G., Vaisburg, A., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800251w · Cited by 113 · see citing works
Glycolipid GD3 and GD3 synthase are key drivers for glioblastoma stem cells and tumorigenicity
Yeh, S.-C., Wang, P.-Y., Lou, Y., Khoo, K., Hsiao, M., Hsu, T.-L., & Wong, C. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1604721113 · Cited by 103 · see citing works
Advances in epigenetic glioblastoma therapy
Lee, D. H., Ryu, H.-W., Won, H.-R., & Kwon, S. H. (2017) · Oncotarget · doi:10.18632/oncotarget.14612 · Cited by 101 · see citing works
Valproic acid sensitizes human glioma cells for temozolomide and γ-radiation
van Nifterik, K. A., den Berg, J. V., Slotman, B. J., Lafleur, M. V. M., Sminia, P., & Stalpers, L. J. A. (2011) · Journal of Neuro-Oncology · doi:10.1007/s11060-011-0725-z · Cited by 99 · see citing works
Ciechomska, I. A., Przanowski, P., Jackl, J., Wojtaś, B., & Kaminska, B. (2016) · Scientific Reports · doi:10.1038/srep38723 · Cited by 86 · see citing works
Self-citationLee, P., Murphy, B., Miller, R., Menon, V., Banik, N. L., Giglio, P., Lindhorst, S., Varma, A. K., Vandergrift, W. A., Patel, S. J., et al. (2015) · PubMed · Cited by 83 · see citing works
Experimental therapy of malignant gliomas using the inhibitor of histone deacetylase MS-275
Eyüpoglu, I. Y., Hahnen, E., Tränkle, C., Savaskan, N. E., Siebzehnrübl, F. A., Buslei, R., Lemke, D., Wick, W., Fahlbusch, R., & Blümcke, I. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0533 · Cited by 71 · see citing works
On glioblastoma and the search for a cure: where do we stand?
Bianco, J. I., Bastiancich, C., Jankovski, A., Rieux, A. D., Véronique Préat, A., & Danhier, F. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2483-3 · Cited by 66 · see citing works
Molecular pathology and clinical characteristics of oligodendroglial neoplasms
Walker, C. A., du Plessis, D., Joyce, K. A., Fildes, D., Gee, A. L., Haylock, B. J., Husband, D. J., Smith, T. S., Broome, J. C., & Warnke, P. C. (2005) · Annals of Neurology · doi:10.1002/ana.20496 · Cited by 65 · see citing works
Is Glioblastoma an Epigenetic Malignancy?
Maleszewska, M., & Kaminska, B. (2013) · Cancers · doi:10.3390/cancers5031120 · Cited by 58 · see citing works
Self-citationThe embryonic type ofSPP1transcriptional regulation is re-activated in glioblastoma
Kijewska, M., Kocyk, M., Kloss, M., Stępniak, K., Korwek, Z., Polakowska, R. R., Dąbrowski, M., Gieryng, A., Wojtaś, B., Ciechomska, I. A., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.14092 · Cited by 58 · see citing works
Self-citationSynthesis and Biological Properties of Novel, Uracil-Containing Histone Deacetylase Inhibitors
Mai, A., Massa, S., Rotili, D., Simeoni, S., Ragno, R., Botta, G., Nebbioso, A., Miceli, M., Altucci, L., & Brosch, G. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm0605536 · Cited by 57 · see citing works
Self-citationZhang, Z., Wang, Y., Chen, J., Tan, Q., Xie, C., Li, C., Zhan, W., & Wang, M. (2016) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-016-3188-2 · Cited by 52 · see citing works
Mai, A., Massa, S., Rotili, D., Pezzi, R., Bottoni, P., Scatena, R., Meraner, J., & Brosch, G. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2005.07.081 · Cited by 51 · see citing works
Self-citationKnockdown of HDAC1 expression suppresses invasion and induces apoptosis in glioma cells
Wang, X., Bai, H., Li, S., Sun, H., Min, L., Tao, B., Zhong, J., & Li, B. (2017) · Oncotarget · doi:10.18632/oncotarget.18227 · Cited by 51 · see citing works
Bien-Möller, S., Balz, E., Herzog, S., Plantera, L., Vogelgesang, S., Weitmann, K., Seifert, C., Fink, M. A., Marx, S., Bialke, A., et al. (2018) · Stem Cells International · doi:10.1155/2018/9628289 · Cited by 43 · see citing works
Molecular Targets in Glioblastoma
Zorzan, M., Giordan, E., Redaelli, M., Caretta, A., & Mucignat‐Caretta, C. (2015) · Future Oncology · doi:10.2217/fon.15.22 · Cited by 39 · see citing works
Cyclosporine a induces growth arrest or programmed cell death of human glioma cells
Żupańska, A. K., Dziembowska, M., Ellert‐Miklaszewska, A., Gawęda-Walerych, K., & Kaminska, B. (2005) · Neurochemistry International · doi:10.1016/j.neuint.2005.05.010 · Cited by 38 · see citing works
Self-citationCiechomska, I. A., Marciniak, M. P., Jackl, J., & Kaminska, B. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01271 · Cited by 38 · see citing works
Self-citationPang, L. Y., Saunders, L., & Argyle, D. J. (2017) · Oncotarget · doi:10.18632/oncotarget.19868 · Cited by 34 · see citing works
Mai, A., Perrone, A., Nebbioso, A., Rotili, D., Valente, S., Tardugno, M., Massa, S., Bellis, F. D., & Altucci, L. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.03.055 · Cited by 31 · see citing works
Self-citationRiva, G., Butta, V., Cilibrasi, C., Baronchelli, S., Redaelli, S., Dalprà, L., Lavitrano, M., & Bentivegna, A. (2016) · Oncology Reports · doi:10.3892/or.2016.4665 · Cited by 29 · see citing works
Maleszewska, M., & Kaminska, B. (2015) · Future Oncology · doi:10.2217/fon.15.171 · Cited by 24 · see citing works
Self-citationJones, N., Rowe, M. R., Shepherd, P. R., & McConnell, M. J. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3510 · Cited by 18 · see citing works
Effects of valproic acid on the susceptibility of human glioma stem cells for TMZ and ACNU
Li, Z., Xia, Y. F., Bu, X., Yang, D., Yuan, Y., Guo, X., Zhang, G., Wang, Z., & Jiao, J. (2018) · Oncology Letters · doi:10.3892/ol.2018.8551 · Cited by 10 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Milazzo, G., Mercatelli, D., Muzio, G. D., Triboli, L., Rosa, P. D., Perini, G., & Giorgi, F. M. (2020) · Genes · doi:10.3390/genes11050556 · Cited by 431 · see citing works
Epigenetic modulation and understanding of HDAC inhibitors in cancer therapy
Ramaiah, M. J., Tangutur, A. D., & Manyam, R. R. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119504 · Cited by 358 · see citing works
Targeting post-translational histone modifying enzymes in glioblastoma
Kunadis, E., Lakiotaki, E., Korkolopoulou, P. A., & Piperi, C. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107721 · Cited by 111 · see citing works
Dexamethasone in Glioblastoma Multiforme Therapy: Mechanisms and Controversies
Cenciarini, M., Valentino, M., Belia, S., Sforna, L., Rosa, P., Ronchetti, S., D’Adamo, M. C., & Pessia, M. (2019) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2019.00065 · Cited by 94 · see citing works
Kim, Y., Park, S.-M., Ha, H. C., Lee, A. R., Won, H., Cha, H., Cho, S., & Cho, J. M. (2020) · Journal of Cancer · doi:10.7150/jca.44622 · Cited by 90 · see citing works
Wang, Y., Abrol, R., Mak, J. Y. W., Gupta, K. D., Ramnath, D., Karunakaran, D., Fairlie, D. P., & Sweet, M. J. (2022) · FEBS Journal · doi:10.1111/febs.16437 · Cited by 67 · see citing works
Mafi, A., Rahmati, A., Aghdam, Z. B., Salami, R., Salami, M., Vakili, O., & Aghadavod, E. (2022) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-022-00354-4 · Cited by 66 · see citing works
Hanisch, D., Krumm, A., Diehl, T., Stork, C. M., Dejung, M., Butter, F., Kim, E. L., Brenner, W., Fritz, G., Hofmann, T. G., et al. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-04751-7 · Cited by 61 · see citing works
HDACs and the epigenetic plasticity of cancer cells: target the complexity
Brancolini, C., Gagliano, T., & Minisini, M. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108190 · Cited by 55 · see citing works
Król, S. K., Kaczmarczyk, A., Wojnicki, K., Wojtaś, B., Gielniewski, B., Grajkowska, W., Kotulska, K., Szczylik, C. A., Czepko, R. A., Banach, M., et al. (2020) · Cancers · doi:10.3390/cancers12102919 · Cited by 49 · see citing works
Self-citationHersh, A. M., Gaitsch, H., Alomari, S., Lubelski, D., & Tyler, B. (2022) · Cancers · doi:10.3390/cancers14153743 · Cited by 47 · see citing works
Xu, Y., Li, P., Liu, Y., Xin, D., Lei, W., Liang, A., Han, W., & Qian, W. (2022) · 癌症：英文版 · doi:10.1002/cac2.12313 · Cited by 45 · see citing works
Bahia, R. K., Hao, X., Hassam, R., Cseh, O., Bozek, D. A., Luchman, H. A., & Weiss, S. (2023) · Nature Communications · doi:10.1038/s41467-023-40776-y · Cited by 34 · see citing works
Al‐Awadhi, F. H., Salvador‐Reyes, L. A., Elsadek, L. A., Ratnayake, R., Chen, Q.-Y., & Luesch, H. (2020) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.0c00093 · Cited by 34 · see citing works
Nonredundant, isoform-specific roles of HDAC1 in glioma stem cells
Lo Cascio, C., McNamara, J. B., Melendez, E. L., Lewis, E. M., Dufault, M. E., Sanai, N., Plaisier, C. L., & Mehta, S. (2021) · JCI Insight · doi:10.1172/jci.insight.149232 · Cited by 33 · see citing works
Stitzlein, L. M., Adams, J. T., Stitzlein, E., Dudley, R. W., & Chandra, J. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02923-7 · Cited by 32 · see citing works
Nepali, K., Hsu, T., Hsieh, C., Lo, W.-L., Lai, M.-J., Hsu, K., Lin, T. E., Chuang, J., & Liou, J. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113338 · Cited by 32 · see citing works
Histone‐deacetylase 8 drives the immune response and the growth of glioma
Mormino, A., Cocozza, G., Fontemaggi, G., Valente, S., Esposito, V., Santoro, A., Bernardini, G., Santoni, A., Fazi, F., Mai, A., et al. (2021) · Glia · doi:10.1002/glia.24065 · Cited by 30 · see citing works
Self-citationEpigenetic alterations in glioblastomas: Diagnostic, prognostic and therapeutic relevance
Montella, L., Cuomo, M., Gaudio, N. D., Buonaiuto, M., Costabile, D., Visconti, R., Risi, T. D., Vinciguerra, R., Trio, F., Ferraro, S., et al. (2022) · International Journal of Cancer · doi:10.1002/ijc.34381 · Cited by 31 · see citing works
Xu, K. M., Ramesh, K. K., Huang, V., Gurbani, S. S., Cordova, J. S., Schreibmann, E., Weinberg, B. D., Sengupta, S., Voloschin, A. D., Holdhoff, M., et al. (2022) · Tomography · doi:10.3390/tomography8020057 · Cited by 28 · see citing works
Garcia-Fabiani, M. B., Haase, S., Comba, A., Carney, S. V., McClellan, B. L., Banerjee, K., Alghamri, M. S., Faisal, S. M., Kadiyala, P., Núñez, F. J., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.631037 · Cited by 28 · see citing works
Ramaiah, M. J., Ramalingam, P. S., Mathavan, S., Yamajala, R. B. R. D., Moparthi, N. R., Kurappalli, R. K., & Manyam, R. R. (2022) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2022.109876 · Cited by 27 · see citing works
The Quest for Non-Invasive Diagnosis: A Review of Liquid Biopsy in Glioblastoma
Elias, M. G., Hadjiyiannis, H., Vafaee, F., Scott, K. F., SOUZA, P. D., Becker, T. M., & Fatima, S. (2025) · Cancers · doi:10.3390/cancers17162700 · Cited by 25 · see citing works
Preclinical and Clinical Applications of Metabolomics and Proteomics in Glioblastoma Research
Ahmed, M., Semreen, A. M., El‐Huneidi, W., Bustanji, Y. K., Abu‐Gharbieh, E., Alqudah, M. A. Y., Alhusban, A., Shara, M., Abuhelwa, A. Y., Soares, N. C., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms24010348 · Cited by 25 · see citing works
Fan, Y., Peng, X., Wang, Y., Li, B., & Zhao, G. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.720020 · Cited by 25 · see citing works
Zając, A. E., Król, S. K., Rutkowski, P. L., & Czarnecka, A. M. (2021) · Cancers · doi:10.3390/cancers13061317 · Cited by 22 · see citing works
Therapeutic Options in Neuro-Oncology
Afonso, M. G., & Brito, M. A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23105351 · Cited by 22 · see citing works
Sesé, B., Ensenyat-Méndez, M., Íñiguez-Muñoz, S., Llinàs‐Arias, P., & Marzese, D. M. (2021) · Clinical Epigenetics · doi:10.1186/s13148-021-01139-w · Cited by 20 · see citing works
Milan, T. M., Eskenazi, A. P. E., Bighetti‐Trevisan, R. L., & Almeida, L. O. (2022) · Archives of Oral Biology · doi:10.1016/j.archoralbio.2022.105468 · Cited by 21 · see citing works
Nepali, K., Wu, A.-C., Lo, W., Chopra, B., Lai, M.-J., Chuang, J., & Liou, J. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.115054 · Cited by 21 · see citing works
DMRTA2 supports glioma stem-cell mediated neovascularization in glioblastoma
Maleszewska, M., Wojnicki, K., Mieczkowski, J., Król, S. K., Jacek, K., Śmiech, M., Kocyk, M., Ciechomska, I. A., Bujko, M., SIEDLECKI, J. A., et al. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-06603-y · Cited by 20 · see citing works
Self-citationLazo, P. A. (2022) · Cancers · doi:10.3390/cancers14164050 · Cited by 19 · see citing works
Introducing HDAC-Targeting Radiopharmaceuticals for Glioblastoma Imaging and Therapy
Everix, L., Seane, E. N., Ebenhan, T., Goethals, I., & Bolcaen, J. (2023) · Pharmaceuticals · doi:10.3390/ph16020227 · Cited by 19 · see citing works
Pająk, B., SİWİAK, E., Jaśkiewicz, A., Sołtyka, M., Zielinski, R. J., Domoradzki, T., Fokt, I., Skóra, S., & Priebe, W. (2021) · Biomedicines · doi:10.3390/biomedicines9121749 · Cited by 18 · see citing works
HDAC-an important target for improving tumor radiotherapy resistance
Ling, R., Wang, J., Fang, Y., Yu, Y., Su, Y., Sun, W., Li, X., & Tang, X. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1193637 · Cited by 19 · see citing works
Pratap, U. P., Sareddy, G. R., Liu, Z., Venkata, P. P., Liu, J., Tang, W., Altwegg, K. A., Ebrahimi, B., Li, X., TEKMAL, R. R., et al. (2021) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdab099 · Cited by 18 · see citing works
Histone Modifying Enzymes and Chromatin Modifiers in Glioma Pathobiology and Therapy Responses
Ciechomska, I. A., Jayaprakash, C., Maleszewska, M., & Kaminska, B. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-30651-9_13 · Cited by 17 · see citing works
Self-citationWang, H., Shi, L., & Wang, Z. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.756817 · Cited by 17 · see citing works
HDAC7: a promising target in cancer
Liu, C., Zheng, D., Pu, X., & Li, S. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1327933 · Cited by 16 · see citing works
Kuodza, G. E., Kawai, R., & LaSalle, J. M. (2024) · Current Zoology · doi:10.1093/eep/dvae023 · Cited by 15 · see citing works
MiR-128-3p – a gray eminence of the human central nervous system
Kiel, K., Król, S. K., Bronisz, A., & Godlewski, J. (2024) · Molecular Therapy Nucleic Acids · doi:10.1016/j.omtn.2024.102141 · Cited by 15 · see citing works
Self-citationGlioblastoma: Molecular features, emerging molecular targets and novel therapeutic strategies
Politis, A. A., Stavrinou, L. C., Kalyvas, A., Boviatsis, E. I., & Piperi, C. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104764 · Cited by 15 · see citing works
Xu, L., Yang, W., Che, J., Li, D., Wang, H., Li, Y., & Zhou, W. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-04571-9 · Cited by 14 · see citing works
Synthetic Betulin Derivatives Inhibit Growth of Glioma CellsIn Vitro
Król, S. K., Bębenek, E., Sławińska-Brych, A., Dmoszyńska‐Graniczka, M., Boryczka, S., & Stepulak, A. (2020) · Anticancer Research · doi:10.21873/anticanres.14635 · Cited by 14 · see citing works
Targeted Epigenetic Interventions in Cancer with an Emphasis on Pediatric Malignancies
Gaál, Z. (2022) · Biomolecules · doi:10.3390/biom13010061 · Cited by 12 · see citing works
Identification of new targets for glioblastoma therapy based on a DNA expression microarray
Larriba, E., Romero, C. D. J., García‐Martínez, A., Quintanar, T., Rodríguez-Lescure, Á., Soto, J. L., Saceda, M., Martín‐Nieto, J., & Barberá, V. M. (2024) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2024.108833 · Cited by 12 · see citing works
The Role of HDAC6 in Glioblastoma Multiforme: A New Avenue to Therapeutic Interventions?
Spallotta, F., & Illi, B. (2024) · Biomedicines · doi:10.3390/biomedicines12112631 · Cited by 12 · see citing works
Fiorentino, F., Fabbrizi, E., Raucci, A., Noce, B., Fioravanti, R., Valente, S., Paolini, C., Maria, R. D., Steinkühler, C., Gallinari, P., et al. (2024) · ChemMedChem · doi:10.1002/cmdc.202300655 · Cited by 11 · see citing works
Self-citationCao, W., Ji, Z., Zhu, S., Wang, M., & Runming, S. (2024) · BMC Medical Genomics · doi:10.1186/s12920-023-01775-6 · Cited by 10 · see citing works
Chemical Perturbations Impacting Histone Acetylation Govern Colorectal Cancer Differentiation
Likasitwatanakul, P., Li, Z., Doan, K. T., Spisák, S., Raghawan, A. K., Liu, Q., Liow, P., Lee, S. L., Chen, D. J., Bala, P., et al. (2025) · Gastroenterology · doi:10.1053/j.gastro.2025.07.003 · Cited by 9 · see citing works
Lu, Y., Feng, Y., Zhao, L., Li, J., Zhang, H., Hu, X., Jiang, W., Shi, T., & Wang, Z. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113908 · Cited by 9 · see citing works
Król, S. K., Bębenek, E., Dmoszyńska‐Graniczka, M., Sławińska-Brych, A., Boryczka, S., & Stepulak, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212299 · Cited by 9 · see citing works
Miles, M. A., Harris, M. A., & Hawkins, C. J. (2019) · APOPTOSIS · doi:10.1007/s10495-019-01543-x · Cited by 7 · see citing works
Menezes, A., Julião, G., Mariath, F., Ferreira, A. L., Oliveira-Nunes, M. C., Gallucci, L., Evaristo, J. A. M., Nogueira, F. C. S., Pereira, D. D. A., & Carneiro, K. (2024) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2024.100722 · Cited by 6 · see citing works
Kotian, S., Carnes, R. M., & Stern, J. L. (2023) · Genes · doi:10.3390/genes14091787 · Cited by 5 · see citing works
Rejimon, A. C., Ramesh, K. K., Trivedi, A. G., Huang, V., Schreibmann, E., Weinberg, B. D., Kleinberg, L. R., Shu, H. G., Shim, H., & Olson, J. J. (2024) · Tomography · doi:10.3390/tomography10030033 · Cited by 5 · see citing works
The Role of Epigenetics in Brain and Spinal Cord Tumors
Park, S. (2023) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-14732-6_8 · Cited by 5 · see citing works
Sixto‐López, Y., Marhuenda, E., García-Vázquez, J. B., Fragoso-Vázquez, M. J., Rosales‐Hernández, M. C., Zacarías-Lara, O., Méndez-Luna, D., Gómez-Vidal, J. A., Cornu, D., Bakalara, N., et al. (2021) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-021-01072-9 · Cited by 4 · see citing works
Khathayer, F. H., & Mikael, M. (2024) · Research Square · doi:10.21203/rs.3.rs-4170668/v1 · Cited by 4 · see citing works
Song, J., Ye, L., Ding, W.-Q., Qiao, H., Dai, J., Bai, H., & Zhang, S. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.09.019 · Cited by 3 · see citing works
Wang, J., Zhou, C., Li, B., Liu, H., Zhang, H., & Liu, L. (2024) · Medicinal Chemistry Research · doi:10.1007/s00044-024-03206-2 · Cited by 3 · see citing works
Gulia, S., Chandra, P., & Das, A. (2024) · Current Computer - Aided Drug Design · doi:10.2174/0115734099279130231211053542 · Cited by 2 · see citing works
Bibliometric and visualization analysis in the field of epigenetics and glioma (2009–2024)
Zeng, Y., Tao, G., Zeng, Y., He, J., Cao, H., & Zhang, L. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1431636 · Cited by 1 · see citing works
Srinageshwar, B., Dunbar, G. L., & Rossignol, J. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-91909-8.00029-3 · Cited by 1 · see citing works
Khathayer, F. H. (2024) · Maǧallaẗ ǧāmiʿaẗ al-Sulṭān Qābūs li-l-ʿulūm/Sultan Qaboos University journal for science · doi:10.53539/squjs.vol29isspp1-14 · Cited by 1 · see citing works
Investigational new drugs against glioblastoma
Kamson, D. O., Khela, H. S., & Laterra, J. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821567-8.00002-6
Brain Disease Mechanisms - Editor’s Picks 2021
Cenciarini, M., Valentino, M., Belia, S., Sforna, L., Rosa, P., Ronchetti, S., D’Adamo, M. C., & Pessia, M. (2021) · Frontiers research topics · doi:10.3389/978-2-88971-063-8
High Glucose modulates the cancer cell fate by regulation of mTOR-HDAC-microRNA axisPreprint
Ramaiah, M. J., Kumar, K. R., Ramalingam, P. S., Moparthi, N. R., Reddy, R., Dirisala, V. R., Rao, K. V., & Naushad, S. M. (2022) · Research Square · doi:10.21203/rs.3.rs-1957231/v1
Khathayer, F. H., & Mikael, M. H. (2024) · Biomedical and Biotechnology Research Journal (BBRJ) · doi:10.4103/bbrj.bbrj_216_24
The histone deacetylase inhibitor CG-745 enhances the radiosensitivity of prostate cancer cells
Wu, B., & Liao, S. (2025) · Journal of International Medical Research · doi:10.1177/03000605251371562
Cao, W., Ji, Z., Zhu, S., Wang, M., & Sun, R. (2024) · Figshare · doi:10.6084/m9.figshare.26659123
Cao, W., Ji, Z., Zhu, S., Wang, M., & Sun, R. (2024) · Figshare · doi:10.6084/m9.figshare.26659126
Liu, Y., Qiu, Q., Deng, H., Song, P., Bu, J., & Zhang, M. (2026) · International Journal of General Medicine · doi:10.2147/ijgm.s583369
Fiorentino, F., Bontempi, G., Michetti, F., Pecci, V., Fabbrizi, E., Passeri, D., Corsetti, L., Farini, V., Casano, F., Gioiello, A., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c02737
Self-citationIdentifying Treatment Related Signatures In Glioblastoma Using KaleidoCellPreprint
Radig, J., Welz, C., Jerome, M. S., Ostheimer, P., Fellenz, S., Radlwimmer, B., & Herrmann, C. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.13.724848
Gayen, S., Sanyal, I., & Roy, S. (2026) · Pharmaceutical Research · doi:10.1007/s11095-026-04115-2
- Authors
- Was, H., Krol, S. K., Rotili, D., Mai, A., Wojtas, B., Kaminska, B., & Maleszewska, M.
- Affiliations
- Sapienza University of Rome (IT)
- Istituto Pasteur (IT)
- Instytut Biologii Doświadczalnej im. Marcelego Nenckiego (PL)
- Corresponding author
- Maleszewska, Marta
- Venue
- Clinical Epigenetics
- Published
- 2019-01-17
- Volume
- 11
- Issue
- 1
- Pages
- 11-11
- ISSN
- 1868-7075 (ISSN-L)
- 1868-7083
- PMC
- PMC6337817
- OpenAlex
- W2912602884
- Cited by
- 78
- References
- 45
- Citations by year
- 2026: 4 · 2025: 5 · 2024: 20 · 2023: 6 · 2022: 17 · 2021: 16 · 2020: 7 · 2019: 3
- FWCI
- 3.64
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Clinical Epigenetics (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Iris (Roma Tre University) (submittedVersion)
- Funders
- Narodowe Centrum Nauki (2013/09/B/NZ3/01402)
- Narodowe Centrum Badań i Rozwoju (STRATEGMED1/233574/15/NCBR/2015 - EPTHERON)
- MIUR (PRIN 20152TE5PK)
- Associazione Italiana per la Ricerca sul Cancro (AIRC 2016/19162)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Health Sciences › Medicine › Genetics › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Keywords
- histone deacetylase inhibitors, glioblastoma, glioma stem cells, HDAC1, HDAC2, HDAC3, HDAC7, epigenetic therapy, cell proliferation, G2/M cell cycle arrest, astrocyte survival, sphere culture, antiproliferative activity
- MeSH terms
- Histone Deacetylase 3, Benzamides, Brain Neoplasms, Cell Adhesion, Cell Survival, Drug Screening Assays, Antitumor, Glioma, Histone Deacetylases, Humans, Pyrimidines, Neoplastic Stem Cells, Up-Regulation, Spheroids, Cellular, DNA Methylation, Epigenesis, Genetic, Cell Line, Tumor, Cell Proliferation, Histone Deacetylase 1, Histone Deacetylase 2, Histone Deacetylase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
